# Cloverna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cloverna

- Industry: Biotechnology
- Headquarters: Kurashiki, Japan
- Website: https://cloverna.com/
- Total disclosed funding: $0.7M
- Latest round: Series A (Aug 30, 2022)
- Investors on record: 1

## About

Based in Kurashiki, Japan, and founded in 2022 by its CEO Tatsuo Ito and co-founder Yurika Shimizu, Cloverna Inc. operates as a research and development company for pharmaceuticals that utilize RNA-targeted drug discovery technology. In August 2022, Cloverna Inc. raised JPY 100 million in venture funding from Keio Innovation Initiative. As of September 2022, the company by its CEO Tatsuo Ito.

Cloverna Inc. offers RNA targeted drug discovery platform that extracts RNA motif sequences to serve as drug discovery targets from a large number of candidates. The company's non-coding RNA is used in diseases such as the development, malignant transformation, and metastasis of cancer (cMYC, etc.), and diseases caused by the accumulation of abnormal proteins such as amyotrophic lateral sclerosis (ALS) and dilated cardiomyopathy (DCM). 

The company plans to use venture funding in the research and development activities of the company for new drug discoveries and the creation of new product pipelines

## Funding rounds

- Series A, Aug 30, 2022, $0.7M — Keio Innovation Initiative

## Investors

- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series A